Research graph
References from Transition from inpatient to outpatient step-up dosing of bispecific antibodies in multiple myeloma: real-world insights. Local targets link to admitted publications; unresolved targets remain external evidence.
Teclistamab in relapsed or refractory multiple myeloma
10.1056/nejmoa2203478 · 2022 · External reference
Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma
10.1056/nejmoa2204591 · 2022 · External reference
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
10.1038/s41591-023-02528-9 · 2023 · External reference
Linvoseltamab for treatment of relapsed/refractory multiple myeloma
10.1200/jco.24.01008 · 2024 · External reference
EHA–EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
10.1038/s41571-025-01041-x · 2025 · External reference
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
10.1016/s1470-2045(24)00043-3 · 2024 · External reference
European expert panel consensus on outpatient administration of teclistamab and talquetamab in patients with multiple myeloma: feasibility, key considerations, and future directions
10.1111/ejh.14444 · 2025 · External reference
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
10.3389/fonc.2025.1630146 · 2025 · External reference
P-286 Impact of hypogammaglobulinemia and immunoglobulin replacement therapy on infection rate in patients with RRMM treated with elranatamab: post-hoc analysis from MagnetisMM-3
10.1016/s2152-2650(23)01904-3 · 2023 · External reference
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
10.1182/bloodadvances.2023011658 · 2024 · External reference
Optec: a phase 2 study to evaluate outpatient step-up administration of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM): updated results
10.1182/blood-2024-207295 · 2024 · External reference
Unresolved reference
External reference
An outpatient model for teclistamab step-up dosing administration – initial experiences at FOX chase cancer center BMT program [abstract]
10.1097/01.hs9.0000970664.60500.7f · 2023 · External reference
Real-world safety outcomes and healthcare resource utilization (HCRU) during outpatient, inpatient, and hybrid step-up dosing (SUD) of teclistamab (Tec) and talquetamab (Tal): a chart review study
10.1016/s2152-2650(25)03524-4 · 2025 · External reference
Prophylactic dexamethasone (dex) with outpatient step-up dosing (SUD) of bispecific antibodies (BsAb) in multiple myeloma (MM) v. standard of care (SOC) inpatient observation
10.1016/s2152-2650(25)03562-1 · 2025 · External reference
Feasibility and safety of outpatient model for administration of bispecific antibodies: proceedings from an International Myeloma Society 21st Annual Meeting oral abstract
10.1016/j.clml.2025.04.002 · 2025 · External reference
Real-world safety and health care resource utilization of teclistamab under an outpatient model for step-up dosing administration
10.1200/op-24-00489 · 2025 · External reference
Bispecific outpatient step-up dosing with prophylactic dexamethasone: the BOSS program experience in myeloma
10.1016/s2152-2650(25)03484-6 · 2025 · External reference
Dexamethasone for the management of CRS related to teclistamab in patients with relapsed/refractory multiple myeloma
10.1038/s41408-025-01222-y · 2025 · External reference
Outpatient step-up dosing of teclistamab (TEC): an implementation process shifting from the academic inpatient (IP) to community outpatient (OP) setting
10.1016/s2152-2650(25)03481-0 · 2025 · External reference
Outcomes of outpatient step-up dosing (SUD) of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma (RRMM): findings from a large network of community practices in the USA
10.1016/s2152-2650(25)03523-2 · 2025 · External reference
Tocilizumab prophylaxis for outpatient administration of teclistamab in relapsed/refractory multiple myeloma
2025 · External reference
Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers
10.1080/03007995.2026.2626367 · 2026 · External reference
Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM) [abstract]
2024 · External reference
MM-216: Prophylactic tocilizumab to mitigate cytokine release syndrome and outpatient dosing of talquetamab in relapsed/refractory multiple myeloma: updated phase 1/2 Monumental-1 results
10.1016/s2152-2650(25)02580-7 · 2025 · External reference
